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Abstract Propionic acidemia (PA) is a rare autosomal reces-
sive organic aciduria resulting from defects in propionyl-CoA-
carboxylase (PCC), a key enzyme of intermediate energy
metabolism. PA mostly manifests during the neonatal period,
when affected newborns develop severe metabolic acidosis
and hyperammonemia. We present a previously healthy teen-
ager, who suffered from acute fatigue and breathlessness. The
patient was tachycardic, displayed a precordial heave and a
systolic murmur. Cardiac investigations revealed severe
dilated cardiomyopathy (DCM). Biochemical work up led to
the diagnosis of PA. Remarkably, this patient of consanguin-
eous Hispanic origin was in a good general health condition
before the acute onset of DCM. Diagnosis of PA was con-
firmed by enzymatic and molecular genetic analysis, the latter
revealing a novel homozygous mutation in the PCCB gene
(c.1229G>A; p.R410Q). Residual PCC enzyme activity of
approximately 14 % of normal was detected in patient’s
lymphocytes and fibroblasts, thereby providing a possible
explanation for the hitherto asymptomatic phenotype.
Conclusion: Isolated DCM, although rare, can be the leading
and/or sole symptom of late-onset PA. Therefore, patients
with DCM should receive a comprehensive diagnostic evalu-
ation including selective screening for inborn errors of
metabolism.
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Abbreviations
ADHS Attention deficit and hyperactivity
syndrome
DCM Dilated cardiomyopathy
ECG Electrocardiography
PA Propionic acidemia
PCCA and
PCCB
Propionyl-CoA carboxylase subunits A
and B
Introduction
Propionyl-CoA-Carboxylase (PCC; EC 6.4.1.3) is a mito-
chondrial biotin-dependent enzyme that catalyzes the conver-
sion of propionyl-CoA to methylmalonyl-CoA, which is fur-
ther metabolized to succinyl-CoA, a substrate of the citric acid
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cycle. PCC is a dodecameric enzyme complex, consisting of
6α- and 6β-subunits, which are encoded by the PCCA and
PCCB genes, respectively. Mutations in either of the two
genes result in propionic acidemia (PA; OMIM #606054), a
rare autosomal recessive disease.
Propionyl-CoA is generated by breakdown of the amino
acids valine, leucine, methionine, and threonine as well as by
the degradation of odd chain fatty acids and cholesterol side
chains. An additional source of propionyl-CoA derives from
colonic anaerobic bacterial fermentation of carbohydrates. In
PA, the impaired conversion of propionyl-CoA to
methylmalonyl-CoA leads not only to intracellular accumula-
tion of propionyl-CoA but also to metabolites such as 3-
hydroxypropionate, propionylglycine, and 2-methylcitrate,
which can be detected by analysis of urinary organic acids [2].
PA mostly presents in the neonatal period with severe
metabolic crisis characterized by metabolic acidosis and
hyperammonemia. Affected newborns suffer from nonspecif-
ic signs such as vomiting, feeding difficulties, and somno-
lence. Late-onset forms of PA have been described in only few
patients, most of whom were suffering from various neuro-
logical deficits including mental retardation, ataxia, or meta-
bolic stroke-like episodes [4].
Cardiac involvement such as prolonged QTc-time and di-
lated cardiomyopathy (DCM) are frequent complications of
PA [7]. Prolonged QTc-time, potentially favoring cardiac ar-
rhythmias, is found in up to 70 % of PA patients beyond
infancy [1]. Up to 23 % of patients with PA are reported to
develop cardiomyopathy during disease course [9]. Acute
onset of disease with cardiomyopathy as the first or only
clinical sign has only been described in three other patients
so far (Table 1) [5, 7].
Here, we present a 16 year old previously healthy patient
who suffered from acute cardiac failure due to DCM as the
first manifesting sign of late-onset PA.
Case report
A 16-year-old male patient presented with dyspnoea on exer-
tion and exercise intolerance for 1 week and was hospitalized
at the intensive care unit. Echocardiographic investigations
revealed a severe DCM with a severely impaired ventricular
function (Fig. 1). The previous medical history was unremark-
able except for a nonproductive cough and generalized my-
opathy for 1 month. However, although he was very athletic,
playing hockey and soccer regularly, on few occasions he
previously complained of nausea and vomiting during endur-
ance sports such as leisure cycling. The patient is the offspring
of consanguineous Hispanic parents and was adopted at the
age of 2 years when he was taken to Switzerland. No further
information with regard to the first 2 years of his life is
available. He was treated with methylphenidate for ADHS
since the age of 6 years. Due to behavioral problems, he
attended special school education. Recent neurocognitive
evaluation showed various mild deficits and an IQ of 83.
On the ICU, therapy for congestive heart failure was im-
mediately initiated and paralleled by a broad diagnostic work
up of DCM. Besides diuretic therapy with furosemide,
spironolactone, and hydrochlorothiazide, continuous infusion
of milrinone was added to support circulation. Upon hemo-
dynamic recovery, this therapy was replaced by angiotensin-
converting enzyme inhibitors (captopril and then enalapril)
and additionally carvedilol. On one occasion, electrocardiog-
raphy (ECG) revealed a slightly prolonged QTc-time (457 ms;
ref. <440). During this short episode, hypomagnesemia
(0.71 mmol/L; ref. 0.74–1.03) and hypokalemia (3.2 mmol/
L; ref. 3.5–5.0) were noticed and immediately treated. There-
after, no further ECG abnormalities occurred. Cardiac angi-
ography including cardiac muscle biopsy was performed.
Histopathological examination of the affected cardiac muscle
showed discrete lymphocyte infiltration but no other patholo-
gy.Multiplex PCR investigations for viral genomic material in
blood and cardiac muscle were negative. Metabolic work up
revea led a markedly e leva ted concent ra t ion of
propionylcarnitine (13.5 μmol/L; ref. <3.5) in the
acylcarnitine profile of a dried bloodspot, whereas free carni-
tine level was in the normal range (32.3 μmol/L; ref. <54.8).
In addition, increased urinary levels of 3-hydroxypropionate
(130 mmol/mol creatinine; ref. <10) and 2-methylcitrate
(110 mmol/mol creatinine; ref. <20), but not methylmalonate
(<10 mmol/mol creatinine; ref. <10) were detected, thus lead-
ing to the diagnosis of PA. In line with these findings, glycine
(417 μmol/L; ref. 147–299) was elevated in the plasma amino
acid profile. Acid–base status revealed no significant abnor-
malities, and all lactate levels were in the normal range.
Diagnosis of PA was confirmed by enzyme activity mea-
surements according to an established method [10]. PCC
activity assays in the patient’s lymphocytes (32.5 pmol/min/
mg protein, lower limit of normal 228) and skin fibroblasts
(39.7 pmol/min/mg protein, lower limit of normal 287) re-
vealed residual activities of 14.3 and 13.8 % of lower limits of
normal, respectively. Activity of methylcrotonyl-CoA carbox-
ylase, another biotin-dependent mitochondrial carboxylase,
was in the normal range, thus pointing away from defects or
deficiencies in biotin metabolism.
Finally, a homozygous mutation in the PCCB-gene
(c.1229G>A; p.R410Q) was identified. After the diagnosis
of PA was made, the patient received L-carnitine (80 mg/kg
bodyweight/day) in addition to treatment for congestive heart
failure. His dietary protein intake was 3 g/kg bodyweight/day
which was limited to 1.5 g/kg bodyweight/day following the
diagnosis. No additional amino acid mixtures were supplied.
Therapy with methylphenidate was stopped due to previously
reported association of methylphenidate and the development
of DCM [8]. After the initiation of the anticongestive therapy,
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his cardiac output improved steadily with the ejection fraction
increasing from an initial value of 25 to 40 % within 10 days.
Notably, this improvement occurred before PAwas diagnosed
and treated. Currently, 4 months after acute onset of DCM, the
patient’s general health condition allows moderate physical
exercise again, although he has not yet fully recovered. On
echocardiography, left-sided chambers remain dilated, with a
mildly to moderately impaired ventricular function (left ven-
tricular ejection fraction stable at 40 %).
Discussion
We report on a young man with acute onset of DCM at
the age of 16 years. Notably, before diagnosis of DCM,
the patient was in a good general health condition. The
behavioral problems necessitating special school educa-
tion were tentatively attributed to an ADHS and to the
patient’s social history. The severe DCM responded
rapidly to congestive heart failure treatment and more-
over was substantiated by an amelioration of ejection
fraction from initially 25 to 40 % within 10 days.
Diagnostic work up for DCM including metabolic
screening led to a strong suspicion of PA, which
prompted us to initiate respective treatment with oral
carnitine and dietary protein restriction. Noteworthy,
the clinical improvement occurred before treatment for
PA was started and thus can be attributed solely to the
effects of DCM therapy. This observation is in line with
reports from other patients, who recovered rapidly after
initiation of DCM treatment (Table 1) [7], although
some PA patients have been reported to require liver
transplantation for therapy-resistant DCM [9].
Diagnosis of PAwas confirmed by enzyme activity assays
in lymphocytes and skin fibroblasts, revealing high residual
PCC activities which may explain the hitherto asymptomatic
course. Patients with relevant residual PCC activity are likely
to live a normal and active life, which may ultimately increase
their risk of developing DCM due to recurrent metabolic
stress, e.g., during endurance exercise.
More recently, the relationship between genotype and
phenotype in PA has been the subject of a limited inves-
tigation [3]. While some mutations are associated with
late-onset PA reflecting a rather mild phenotype, certain
mutations are known to cause a more severe phenotype
[3]. Molecular genetic analysis of the patient revealed a
novel homozygous mutation in the PCCB gene. Interest-
ingly, the same mutation has previously been described in
monoallelic form in a 14-year-old male late-onset PA
patient with isolated DCM and compound heterozygosity
(p.R410Q/IVS7+2 T>G; Table 1) [5]. Theoretically, this
specific mutation may predispose towards the develop-
ment of cardiomyopathy. Therefore, it would be of inter-
est to determine the genotype in additional patients with
PA-associated DCM. However, another mutation affecting
the same residue (p.R410W), which is one of three fre-
quent PCCB gene mutations in Japanese PA patients, is
Table 1 Patients with cardiomyopathy (CM) leading to diagnosis of late-onset propionic acidaemia (PA)
Patient,
sex
Age at
onset of CM
Acute therapy Clinical course/recovery
after diagnosis
PCC activity Genotype
(PCCB gene)
Referencea
1, m 6 years Diuretics and inotropes Rapid recovery; asymptomatic
2 months after onset of CM
Unknown Unknown [7]
2, f 13 months Diuretics and bicarbonate Rapid recovery within 1 week Unknown Unknown
3, m 14 years Cardiac transplantation Rapid recovery after cardiac
transplantation
19.9 %b IVS7+2 T>G; p.R410Q [5]
4, m 16 years Diuretics and inotropes Rapid recovery within 2 months 14.3b and 13.8 %c Homozygous for p.R410Q Present
case
m Male, f female
a Reference search was restricted to PubMed. Search restrictions were: “propionic acidemia or propionic acidaemia and cardiomyopathy”
b PCC activity in lymphocytes and c fibroblasts: percentage of normal lower limits
Fig. 1 Dilated cardiomyopathy on echocardiography. Initial echocardi-
ography of the patient showing severe dilated cardiomyopathy. LV left
ventricle, LA left atrium, RV right ventricle, RA right atrium
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not associated with an increased risk towards the devel-
opment of DCM [11].
Pathophysiology underlying the PA-associated cardiomy-
opathy remains unclear and different hypotheses have been
brought up. One aspect is a potential harm to cardiomyocytes
through the accumulation of toxic byproducts such as 3-
hydroxypropionate and 2-methylcitrate. However, recent
studies by Romano et al. [9] did not find a correlation
between excretion of propionate metabolites in urine and
occurrence of cardiomyopathy. Although we cannot rule
out such an effect, cardiac muscle biopsy samples of our
patient lacked signs of previous damage such as tissue fibro-
sis or necrosis. Deficiency in free carnitine [6, 7] as well as
biotin deficiency has been suggested as potential risk factors
for the development of cardiomyopathy in PA patients. In
our patient, normal free carnitine levels in dried blood make
carnitine deficiency unlikely. PCC activity did not respond to
biotin supplementation in vitro, rendering biotin deficiency
unlikely. Although methylphenidate probably did not con-
tribute to DCM, therapy was stopped due to reported cases
of methylphenidate-associated DCM [8]. Other hypotheses
suggest a more general impairment of energy metabolism by
depletion of the anaplerotic metabolite succinyl-CoA or sec-
ondary respiratory chain deficiencies as favoring the onset of
cardiomyopathy [6]. However, the inconsistent relationship
between the development of DCM and the frequency of
metabolic decompensations remains unexplained.
While the differential diagnosis of DCM is diverse and
most commonly associated with infectious pathogens, it
seems prudent to also consider the rare causes such as PA.
Therefore, regardless of their age, patients with DCM need to
undergo a comprehensive diagnostic evaluation including
selective screening for metabolic diseases.
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